Eli Lilly becomes first health-care company to hit $1 trillion

"The Indianapolis-based drugmaker enjoyed a massive 35% boost in its stock price this year, tapping into the rise of weight loss drugs with its own offering, tirzepatide. Lilly's star drugs, Mounjaro and Zepbound, both package tirzepatide, with the former approved to treat Type 2 diabetes and the latter prescribed for weight loss or sleep apnea. Tirzepatide works by simulating two naturally-occurring gut hormones that influence digestion, appetite and help the body regulate blood sugar."

"Lilly's two hot weight loss drugs earned the company more than $10 billion in the third quarter of the year, accounting for more than half of its $17.6 billion in sales during the same period. By the end of October, Mounjaro and Zepbound had already made the company $25 billion - more than the drugmaker's total revenue in 2020. Keeping its growth"

Eli Lilly topped a market capitalization of $1 trillion, becoming the first company in the health industry to reach that level. The stock rose about 35% this year, placing Lilly just outside the global top ten most valuable companies. The surge was driven by strong demand for tirzepatide, marketed as Mounjaro for Type 2 diabetes and Zepbound for weight loss or sleep apnea. Tirzepatide mimics two gut hormones that affect digestion, appetite and blood sugar regulation. Mounjaro and Zepbound generated over $10 billion in third-quarter sales and $25 billion by October, outpacing 2020 revenue. Sustaining growth will require further drug development and commercialization efforts.

Read at Fast Company